Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,001 to 3,020 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular) | 54 of 1,206 49 of 1,220 | 0.5 points -1.2 to 2.1 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization | 185 of 1,206 141 of 1,220 | 3.8 points 1.1 to 6.5 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR) | 104 of 1,206 65 of 1,220 | 3.3 points 1.3 to 5.4 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI | 181 of 1,206 159 of 1,220 | 2.0 points -0.8 to 4.7 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF) | 200 of 1,206 153 of 1,220 | 4.0 points 1.2 to 6.9 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR) | 107 of 1,206 65 of 1,220 | 3.5 points 1.5 to 5.6 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR) | 82 of 1,206 66 of 1,220 | 1.4 points -0.5 to 3.3 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI) | 145 of 1,206 119 of 1,220 | 2.3 points -0.2 to 4.8 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR) | 281 of 1,206 239 of 1,220 | 3.7 points 0.4 to 7.0 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR | 80 of 1,206 65 of 1,220 | 1.3 points -0.6 to 3.2 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF) | 246 of 1,206 203 of 1,220 | 3.8 points 0.7 to 6.8 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI) | 126 of 1,206 94 of 1,220 | 2.7 points 0.5 to 5.0 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE) | 217 of 1,206 178 of 1,220 | 3.4 points 0.5 to 6.3 | 2,426 | NCT02173379 Absorb IV Randomized Controlled Trial |
| FluLaval™ Quadrivalent Group vs Fluzone® Quadrivalent Group: serious adverse events | 5 of 1,207 4 of 1,217 | 0.1 points -0.5 to 0.7 | 2,424 | NCT02242643 Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age |
| Early ART vs Deferred ART: Transmission Risk Behavior Outcome 1 | 156 of 1,236 155 of 1,187 | -0.4 points -3.1 to 2.2 | 2,423 | NCT00867048 Strategic Timing of Antiretroviral Treatment |
| Vitamin D (Cholecalciferol) vs Placebo: deaths from any cause | 5 of 1,211 5 of 1,212 | 0.0 points -0.6 to 0.6 | 2,423 | NCT01942694 Vitamin D and Type 2 Diabetes Study |
| Vitamin D (Cholecalciferol) vs Placebo: Time to Development of Diabetes | 293 of 1,211 323 of 1,212 | -2.5 points -5.9 to 1.0 | 2,423 | NCT01942694 Vitamin D and Type 2 Diabetes Study |
| Vitamin D (Cholecalciferol) vs Placebo: serious adverse events | 173 of 1,211 153 of 1,212 | 1.7 points -1.1 to 4.4 | 2,423 | NCT01942694 Vitamin D and Type 2 Diabetes Study |
| BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: Time to First Severe Asthma Exacerbation, Treatment Policy Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) | 64 of 1,209 114 of 1,212 | -4.1 points -6.2 to -2.0 | 2,421 | NCT05505734 A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma |
| BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) | 62 of 1,209 110 of 1,212 | -3.9 points -6.0 to -1.9 | 2,421 | NCT05505734 A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma |
Code
curl "https://conductscience.org/api/comparisons/v1?page=151"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=151
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02173379-263b6dc5",
"title": "Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)",
"summary": "54 of 1206 against 49 of 1220; risk difference 0.5 points, 95% interval -1.2 to 2.1; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-263b6dc5",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2426,
"risk_difference": {
"value": 0.004612184976755564,
"lower": -0.011612378938061333,
"upper": 0.020954656285816768
},
"group_1": "54 of 1,206",
"group_2": "49 of 1,220",
"difference": "0.5 points",
"interval": "-1.2 to 2.1",
"trial_title": "Absorb IV Randomized Controlled Trial"
},
{
"id": "NCT02173379-4d3e90dc",
"title": "Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization",
"summary": "185 of 1206 against 141 of 1220; risk difference 3.8 points, 95% interval 1.1 to 6.5; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-4d3e90dc",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2426,
"risk_difference": {
"value": 0.03782589783323817,
"lower": 0.01067639062632417,
"upper": 0.06502822535423161
},
"group_1": "185 of 1,206",
"group_2": "141 of 1,220",
"difference": "3.8 points",
"interval": "1.1 to 6.5",
"trial_title": "Absorb IV Randomized Controlled Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=152",
"request_id": "kiuUnZS05I-BtJuW"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant